News By: acrp.admin

Dartmouth-Hitchcock Health just helped open two Phase III COVID-19–related therapeutic studies in six business days. The Gilead-sponsored studies, one of patients with moderate COVID-19 and the other with patients suffering more serious symptoms, are evaluating the safety and antiviral activity of Remdesivir (GS-5734™) against the condition.

Lung cancer clinical trials supported by the pharmaceutical industry demonstrate no more bias than studies funded by other sources, according to a recent study published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.

Clinical research study sites are rapidly becoming more concerned about coronavirus-related interruptions to clinical trial recruitment and retention, with domestic site concern levels jumping from 25% to 47% as of […]

Clinical trial professionals from far and wide are sharing their stories of perseverance and inspiration as the industry comes together to try and conduct clinical trials in the wake of […]

Enlightened souls maintain it’s better to give than to receive—and two leading clinical trial practitioners at the Duke Clinical Research Institute (DCRI) think it’s high time an industry so dependent […]